Gainesville, FL, October 07, 2015 --(PR.com
)-- Xhale Assurance, developer of the Nasal Alar SpO2 ™ Sensor, to be exhibiting at Air Medical Transport Conference & ANESTHESIOLOGY™ 2015 Annual Meeting in October.
Xhale Assurance, Inc., developer of the Nasal Alar SpO2 Sensor, announced that they will have booths at two conferences in October. These conferences are:
• The Air Medical Transport Conference (AMTC) in Long Beach, CA – October 19-21, 2015; Booth # 246.
• The ANESTHESIOLOGY® 2015 annual meeting to be held October 24-28, 2015 at The San Diego Convention Center in San Diego, California; Booth # 4315.
Xhale will be demonstrating the latest generation of its Nasal Alar Sp02 sensor that received FDA 510k clearance in March 2015 and CE Mark in August 2015.
Previous meetings of these professional groups highlighted problems with current SpO2 technologies and Xhale Assurance will demonstrate how the Nasal Alar SpO2 Sensor addresses the significant need for consistently reliable SpO2 readings.
Assurance’s Nasal Alar SpO2 sensor, which is applied to the nasal ala, often detects SpO2 changes faster than a finger-applied sensor, especially in the presence of poor peripheral perfusion, an early response that can be critical for timely clinical intervention.
Xhale, Inc. is a medical technology company developing and commercializing patient-centric monitoring solutions for the healthcare industry. Xhale is focused on developing two broad technology platforms. Through its Xhale Smart, Inc. subsidiary, Xhale is developing a medication adherence monitoring technology – the SMART® Adherence System – designed to verify, monitor, report, and improve adherence to medication regimens in clinical trials. The SMART® Adherence System is the only technology designed to offer definitive and noninvasive monitoring of medication adherence in near real-time, utilizing exhaled breath to confirm that medication has been taken as directed. Through its Xhale Assurance, Inc. subsidiary, Xhale is developing a patient monitoring technology, the Assurance® platform, designed to improve and expand the use of conventional pulse oximetry used in hospitals and other clinical settings to monitor critical patient parameters, as well as to increase the number of parameters which can be measured. Xhale’s first product based on this technology, the Assurance® Nasal Alar SpO2™ Sensor, received marketing clearance in the United States and has received CE Mark approval. The Assurance® Nasal Alar SpO2™ Sensor pulse oximetry sensor is a disposable sensor placed on a patient’s nasal ala which transmits heart rate and blood oxygenation information to an oximetry monitor.
Xhale, Inc. was founded in 2005 on technology licensed from the University of Florida.
For more information, please visit www.xhale.com/assurance or contact the company at firstname.lastname@example.org